Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs.

ABSTRACT:

Background

There is no widely accepted standard medical treatment for apocrine gland anal sac adenocarcinoma (AGASACA) in dogs. Targeted agents such as toceranib may be effective in treatment of AGASACA, but the number of clinical reports investigating its efficacy is limited.

Hypothesis/aim

To evaluate the efficacy of toceranib treatment of AGASACA in dogs, and to assess prognostic factors in the study population. Our hypothesis was that toceranib would provide a clinical benefit in the treatment of dogs with AGASACA.

Animals

Thirty-six client-owned dogs with either a cytologic or histologic diagnosis of AGASACA that were treated with toceranib alone or in combination with surgery, nonconcurrent chemotherapy or both.

Methods

Retrospective study.

Result

SUBMITTER: Heaton CM 

PROVIDER: S-EPMC7096647 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature